Showing results (91-100 of 119) with videos related to
Sort By:
Pageof 12
Magnetic Resonance in Medicine|April 19, 2008
Quantification of viable tumor microvascular characteristics by multispectral analysisLeanne R Berry, Kai H Barck, Mary Ann Go, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 15, 2016
A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid TumorsAnthony W Tolcher, Johanna C Bendell, Kyriakos P Papadopoulos, et al.Science (New York, N.Y.)|July 5, 2008
Laser altimeter observations from MESSENGER's first Mercury flybyMaria T Zuber, David E Smith, Sean C Solomon, et al.The EMBO Journal|August 2, 2000
FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene familyI N Holcomb, R C Kabakoff, B Chan, et al.Proceedings of the National Academy of Sciences of the United States of America|March 27, 2013
Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitmentVernon T Phan, Xiumin Wu, Jason H Cheng, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2015
Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio TrialThomas Sandmann, Richard Bourgon, Josep Garcia, et al.Proceedings of the National Academy of Sciences of the United States of America|March 16, 2007
Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodiesHans-Peter Gerber, Xiumin Wu, Lanlan Yu, et al.Cancer Research|May 1, 2002
Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugateSarajane Ross, Susan D Spencer, Ilona Holcomb, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2016
Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid TumorsJeffrey R Infante, Antoine Hollebecque, Sophie Postel-Vinay, et al.Cancer Cell|January 16, 2007
Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growthQi Pan, Yvan Chanthery, Wei-Ching Liang, et al.Pageof 12